Patents for A61P 35 - Antineoplastic agents (221,099)
07/2007
07/31/2007US7250262 For the diagnosis and treatment of patients with disorders including anemias
07/31/2007US7250256 Its expression products can be used to provide reagents and methods for detecting neoplasia
07/31/2007US7250168 Oxidative damage and protease activity resistance; catalytic efficiency; deep vein thrombosis, disseminated intravascular coagulation, acute coronary syndrome
07/31/2007US7250165 Anti-TNF antibodies, compositions, methods and uses
07/31/2007CA2544381C Methods for administration of a farnesyl dibenzodiazepinone
07/31/2007CA2412596C Cyclic gmp-specific phosphodiesterase inhibitors
07/31/2007CA2398353C Anticancer compound and enantiomer separation method useful for synthesizing said compound
07/31/2007CA2284863C Active substance and composition inhibiting tumorous proliferation in ectoderm derived tissues
07/31/2007CA2212118C Piperidinyl-2-alkyl subst. linear polyamines for the reduction of intracellular, endogenic polyamine levels such as putrescine, spermidine and spermine, and their impact on cell proliferation
07/31/2007CA1341537C Production of pluripotent granulocyte colony-stimulating factor
07/26/2007WO2007084868A2 Treatment of disorders by activation of the unfolded protein response
07/26/2007WO2007084857A2 Methods and compositions for treating cell proliferative disorders
07/26/2007WO2007084786A1 Pyrimidine derivatives used as pi-3 kinase inhibitors
07/26/2007WO2007084672A2 Monoclonal antibodies against cd30 lacking in fucosyl and xylosyl residues
07/26/2007WO2007084670A2 Specific therapy using integrin ligands for treating cancer
07/26/2007WO2007084667A2 Fused heterobicyclic kinase inhibitors
07/26/2007WO2007084498A1 Piperazine derivatives as farnesyl protein transferase inhibitors
07/26/2007WO2007084388A2 Nogo-b receptor
07/26/2007WO2007083823A1 Androgen receptor-binding activity of genoderma mushroom-treated product
07/26/2007WO2007083763A1 Method for production of emulsion preparation comprising physiologically active peptide, and kit for production of the preparation
07/26/2007WO2007083603A1 Therapeutic agent
07/26/2007WO2007083522A1 Gel-forming composition for medical use, devices for the application of the composition, and drug release controlling carrier
07/26/2007WO2007083175A1 Antiviral bifunctional molecules, methods of construction and methods of treating virus-induced cancer therewith
07/26/2007WO2007083114A1 Alchemix for the treatment of cancer
07/26/2007WO2007083101A2 Use in an alternative treatment of cancer
07/26/2007WO2007083089A1 Chemical compounds
07/26/2007WO2007082946A1 Solid forms of a pyrrolopyrimidine derivative and their use as anti-tumor agents
07/26/2007WO2007082882A1 Substituted indolyl-alkyl-amino-derivatives as inhibitors of histone deacetylase
07/26/2007WO2007082880A1 Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
07/26/2007WO2007082878A1 Aminophenyl derivatives as novel inhibitors of histone deacetylase
07/26/2007WO2007082876A1 Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
07/26/2007WO2007082874A1 Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
07/26/2007WO2007082873A1 Heterocyclylalkyl derivatives as novel inhibitors of histone deacetylase
07/26/2007WO2007082805A1 Cis-4, 5-biaryl-2-heterocyclic-imidazolines as mdm2 inhibitors
07/26/2007WO2007082742A1 Isolated organ perfusion combination therapy of cancer
07/26/2007WO2007082483A1 Medicament for treatment of tumor and the use thereof
07/26/2007WO2007082482A1 Novel compound for treatment of tumor
07/26/2007WO2007082475A1 Novel ent-kaurene diterpene compound and its derivatives, their preparation and their use
07/26/2007WO2007082470A1 Pyrrolo-pyridazine derivatives,their preparation methods and uses
07/26/2007WO2007082434A1 Quinazoline derivatives,preparation methods and uses thereof
07/26/2007WO2007082352A1 Method of treatment, prophylaxis and diagnosis of pathologies of the bone
07/26/2007WO2007071393A3 Sulphonamidoaniline derivatives being janus kinases inhibitors
07/26/2007WO2007067781A3 9-membered heterobicyclic compounds as inhibitors of protein kinases
07/26/2007WO2007064993A3 Bicyclic protein kinase inhibitors
07/26/2007WO2007064945A3 Cancer therapies and pharmaceutical compositions used therein
07/26/2007WO2007062175A3 Spiro-substituted tricyclic heterocycles cxcr3 antagonists
07/26/2007WO2007054292A3 Azonafide derivatives, methods for their production and pharmaceutical compositions therefrom
07/26/2007WO2007044441A3 Use of pyrazolo [1 , 5 -a] pyrimidine derivatives for inhibiting protein kinases methods for inhibiting protein kinases
07/26/2007WO2007042573A3 Compositions and methods for treating proliferative disorders
07/26/2007WO2007040650A9 Apoptosis promoters
07/26/2007WO2007026078A3 T cd4+ epitopes of mage-a antigens restricted to hla-dp4 and the use thereof
07/26/2007WO2007003948A3 Core 2 glcnac-t inhibitors
07/26/2007WO2006084264A3 Cd20 antibody variants and uses thereof
07/26/2007WO2006060533A3 Conjugates of 1, 8-bis-naphthalimides with an antibody
07/26/2007US20070173548 Malonamic acids and derivatives thereof as thyroid receptor ligands
07/26/2007US20070173537 Indazole compound and pharmaceutical use thereof
07/26/2007US20070173535 Oxadiazoles having antiproliferative activity
07/26/2007US20070173525 Receptor or non-receptor types; 5,6,7,8,9,10-hexahydro-6,9-(epiminomethano) benzo[ alpha ][8]annulenes; anticarcinogenic, agents; retinal vascularization
07/26/2007US20070173518 Crystal of ticagrelor; G-protein coupled receptor antagonist, used for treating arterial thrombotic complications
07/26/2007US20070173502 Novel urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and novel use
07/26/2007US20070173454 Administering an agent that decreases or regulates the blood level, production, function or activity of gonadotropins-leutinizing hormone, follicle stimulating hormone, activin or follistatin; parkinson's disease
07/26/2007US20070173436 Compositions and methods for enhancing drug delivery across and into epithelial tissues
07/26/2007US20070172920 Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
07/26/2007US20070172532 Complex Mixtures Exhibiting Selective Inhibition of Cyclooxygenase-2
07/26/2007US20070172488 cell proliferation-inhibiting activity by ADCC (antibody-dependent cell-mediated cytotoxicity) activity and CDC (complement-dependent cytotoxicity); hepatic cancer
07/26/2007US20070172455 Chimeric Interleukin-6 Soluble Receptor/Ligand Protein, Analogs Thereof and Uses Thereof
07/26/2007US20070172450 Modulation of immune response and methods based thereon
07/26/2007US20070172447 Agent for preventing and/or treating tissue disruption-accompanied diseases
07/26/2007US20070172435 Medicament for internal application, in particular against cancerous diseases
07/26/2007DE102005058455A1 Composition, useful for e.g. caring of skin and/or for removing skin impurities, comprises an aqueous solution, saturated with fruit sugar; and an unpurified toxin obtained from spiders of the species e.g. Ischnocolus, and bee's honey
07/26/2007CA2672094A1 Methods and apparatus for identifying subject matter in view data
07/26/2007CA2637698A1 Medicament for treatment of a tumor comprising a endostatin and polyethylene glycol conjugate
07/26/2007CA2637687A1 Arginine deiminase conjugate for the treatment of tumours
07/26/2007CA2637635A1 Gel-forming composition for medical use, administration device for the composition, and drug release controlling carrier
07/26/2007CA2637572A1 Piperazine derivatives as farnesyl protein transferase inhibitors
07/26/2007CA2637540A1 Isolated organ perfusion combination therapy of cancer
07/26/2007CA2637387A1 Specific therapy using integrin ligands for treating cancer
07/26/2007CA2637385A1 Compounds for the treatment of inflammatory disorders
07/26/2007CA2637350A1 Method of treatment, prophylaxis and diagnosis of pathologies of the bone
07/26/2007CA2636993A1 Pyrimidine derivatives used as pi-3 kinase inhibitors
07/26/2007CA2636954A1 Solid forms of a pyrrolopyrimidine derivative and their use as anti-tumor agents
07/26/2007CA2636824A1 Cis-4,5-biaryl-2-heterocyclic-imidazolines as mdm2 inhibitors
07/26/2007CA2636579A1 Compositions and methods of use for antibodies of dickkopf-1 and/or -4
07/26/2007CA2636120A1 Chemical compounds
07/26/2007CA2635899A1 Fused heterobicyclic kinase inhibitors
07/26/2007CA2635015A1 Substituted indolyl-alkyl-amino-derivatives as inhibitors of histone deacetylase
07/26/2007CA2633100A1 Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
07/26/2007CA2631876A1 Aminophenyl derivatives as inhibitors of histone deacetylase
07/26/2007CA2631874A1 Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
07/26/2007CA2630717A1 Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
07/26/2007CA2630273A1 Heterocyclylalkyl derivatives as inhibitors of histone deacetylase
07/25/2007EP1811035A1 Aspartic proteinase 2 (ASP2)
07/25/2007EP1811033A1 Cell-permeable peptide inhibitors of the JNK signal transduction pathway
07/25/2007EP1811024A1 Oligo double-stranded rna and medicinal composition
07/25/2007EP1810968A2 9, 10-a, a-OH-texane analogs and methods for production thereof
07/25/2007EP1810715A2 Combination comprising an agent decreasing VEGF activity and an agent decreasing EGF activity
07/25/2007EP1810691A2 Immunotherapy for reversing immune suppression
07/25/2007EP1810688A1 Pharmaceutical preparation containing coated magnetic particles and method for production thereof, and diagnosis therapy system
07/25/2007EP1810684A2 Anticancer agent
07/25/2007EP1810683A1 Immunopotentiator and method and apparatus for producing the same